Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Operating Leases (2022 - 2025)

PAVmed has reported Operating Leases over the past 4 years, most recently at $2.2 million for Q4 2025.

  • For Q4 2025, Operating Leases changed 0.04% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $2.2 million, changed 0.04%, while the annual FY2025 figure was $2.2 million, 0.04% changed from the prior year.
  • Operating Leases for Q4 2025 was $2.2 million at PAVmed, up from $1.8 million in the prior quarter.
  • Over five years, Operating Leases peaked at $5.2 million in Q1 2023 and troughed at $1.8 million in Q3 2025.
  • A 4-year average of $3.1 million and a median of $2.6 million in 2023 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: surged 146.1% in 2023 and later tumbled 57.81% in 2025.
  • Year by year, Operating Leases stood at $3.0 million in 2022, then decreased by 0.9% to $3.0 million in 2023, then decreased by 24.09% to $2.2 million in 2024, then rose by 0.04% to $2.2 million in 2025.
  • Business Quant data shows Operating Leases for PAVM at $2.2 million in Q4 2025, $1.8 million in Q3 2025, and $2.0 million in Q2 2025.